| NCT ID | NCT03819738 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Condition | Epilepsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2017-03-24 |
| Primary Completion | 2025-01-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2017-03-24 with a primary completion date of 2025-01-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
With fMRI, we want to understand the mechanisms of brain neuromodulation in (dys)functional brain circuits, to obtain knowledge on involved brain networks in DBS.
Eligibility Criteria
Inclusion Criteria: * Deep brain stimulation system implanted Exclusion Criteria: * Children and pregnant women will be excluded. Failure to follow to protocol is also an exclusion criterion.
Contact & Investigator
Tom Theys, PhD
PRINCIPAL INVESTIGATOR
Universitaire Ziekenhuizen KU Leuven
Frequently Asked Questions
Who can join the NCT03819738 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03819738 currently recruiting?
Yes, NCT03819738 is actively recruiting participants. Contact the research team at tom.theys@uzleuven.be for enrollment information.
Where is the NCT03819738 trial being conducted?
This trial is being conducted at Leuven, Belgium.
Who is sponsoring the NCT03819738 clinical trial?
NCT03819738 is sponsored by Universitaire Ziekenhuizen KU Leuven. The principal investigator is Tom Theys, PhD at Universitaire Ziekenhuizen KU Leuven. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.